Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696260 | 0.84 | SERPINE1 (0.43) | KMT2AKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL30524282 | 0.84 | SERPINE1 (0.43) | KMT2AKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL57099 | 0.82 | GRM4 (0.44) | GRM4KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL29549932 | 0.82 | GRM4 (0.44) | GRM4KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL57100 | 0.80 | KMT2A (0.44) | GRM4KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL6959141 | 0.80 | GRM4 (0.43) | GRM4KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL874329 | 0.78 | PTGS2 (0.57) | KDM4EALDH1A1LMNAHPGDMAPK1 | |
| SCHEMBL17796977 | 0.78 | KMT2A (0.43) | GRM4KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL2137125 | 0.77 | FABP7 (0.39) | KMT2AKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL9860557 | 0.77 | MAPT (0.58) | GRM4KMT2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957212-B2 | Photobase generator | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2368875-B1 | PHOTOBASE GENERATOR | WAKO PURE CHEM IND LTD (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143257-B2 | inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester | PTC THERAPEUTICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110233048-A1 | PHOTOBASE GENERATOR | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2368875-A1 | PHOTOBASE GENERATOR | Wako Pure Chemical Industries, Ltd. (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | NOVO NORDISK A/S (DK) | 2002-06-27 | — | — | US | disclosed |
| WO-2001087843-A1 | COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED | NOVO NORDISK A/S (DK) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110233048-A1 | PHOTOBASE GENERATOR | CYBA, CRY1, GNB1 | GRM4 4123/4885KMT2A 2516/4885KDM4E 3712/4885 |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | GRM4 4053/4885KMT2A 3045/4885KDM4E 358/4885 |
| US-20020082254-A1 | Compounds for treating disorders where a decreased level of plasma FFA is desired | FABP1, FFAR2, FFAR1 | GRM4 719/4885KMT2A 4207/4885KDM4E 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.